These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9512874)

  • 21. Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
    Harada N; Kashiwagi A; Nishio Y; Kikkawa R
    Diabetes Res Clin Pract; 1999 Feb; 43(2):111-20. PubMed ID: 10221663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study.
    Yoshida H; Ishikawa T; Ayaori M; Shige H; Ito T; Suzukawa M; Nakamura H
    Atherosclerosis; 1998 Jul; 139(1):179-87. PubMed ID: 9699906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability.
    Kroon AA; Demacker PN; Kleinveld HA; Stalenhoef AF
    Atherosclerosis; 1999 Nov; 147(1):105-13. PubMed ID: 10525131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS.
    Gaddi A; Arca M; Ciarrocchi A; Fazio S; D'Alò G; Tiozzo R; Descovich GC; Calandra S
    Metabolism; 1991 Oct; 40(10):1074-8. PubMed ID: 1658544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
    Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
    Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients.
    Tamura A; Watanabe T; Nasu M
    Circ J; 2003 Oct; 67(10):816-20. PubMed ID: 14578611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
    Guérin M; Dolphin PJ; Talussot C; Gardette J; Berthézène F; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1359-68. PubMed ID: 7670950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein.
    Lynch SM; Campione AL; Moore MK
    Biochim Biophys Acta; 2000 May; 1485(1):11-22. PubMed ID: 10802245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group.
    Rubenfire M; Maciejko JJ; Blevins RD; Orringer C; Kobylak L; Rosman H
    Arch Intern Med; 1991 Nov; 151(11):2234-40. PubMed ID: 1953228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers.
    Fuller CJ; Grundy SM; Norkus EP; Jialal I
    Atherosclerosis; 1996 Jan; 119(2):139-50. PubMed ID: 8808491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
    Hussein O; Shneider J; Rosenblat M; Aviram M
    J Cardiovasc Pharmacol; 2002 Jul; 40(1):28-34. PubMed ID: 12072574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.
    Sakabe K; Fukuda N; Wakayama K; Nada T; Shinohara H; Tamura Y
    Circ J; 2003 Oct; 67(10):866-70. PubMed ID: 14578621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cacao liquor polyphenols on the susceptibility of low-density lipoprotein to oxidation in hypercholesterolemic rabbits.
    Osakabe N; Natsume M; Adachi T; Yamagishi M; Hirano R; Takizawa T; Itakura H; Kondo K
    J Atheroscler Thromb; 2000; 7(3):164-8. PubMed ID: 11480458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs.
    Wiklund O; Bondjers G; Wright I; Camejo G
    Atherosclerosis; 1996 Jan; 119(1):57-67. PubMed ID: 8929256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pravastatin effects on lipoproteins, Lp (a), apo B and apo A-1 in patients with primary hypercholesterolemia].
    Novazzi JP; Fonseca FA; Feres MC; da Silva RC; Lima JC; Martinez TL
    Arq Bras Cardiol; 1994 Jun; 62(6):395-8. PubMed ID: 7826229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fish oil lowers plasma lipid concentrations and increases the susceptibility of low density lipoprotein to oxidative modification in healthy men.
    Tsai PJ; Lu SC
    J Formos Med Assoc; 1997 Sep; 96(9):718-26. PubMed ID: 9308326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
    Bhatnagar D; Durrington PN; Kumar S; Mackness MI; Dean J; Boulton AJ
    Diabetes; 1995 Apr; 44(4):460-5. PubMed ID: 7698516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.